Achillion announces proposed secondary offering of common stock
Achillion Pharmaceuticals announced that Johnson & Johnson Innovation-JJDC,, an existing stockholder, intends to offer for sale in an underwritten public offering 18,367,346 shares of Common Stock of Achillion, which constitutes all of JJDC's equity position in Achillion. November 14, 2017